– TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Mar-Jac Poultry MS, LLC Surpasses One Million Man-Hours Without a Lost-Time Incident, Setting New Safety Benchmark - May 6, 2025
- Camwood Capital Group Strengthens Leadership Team with Appointments of Interim CFO Brandon McNally and Interim CTO Dan Cowan - May 6, 2025
- Annual NMDP(SM) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell Therapy - May 6, 2025
